E

Editas Medicine
D

EDIT

1.92000
USD
-0.14
(-6.80%)
مغلق
حجم التداول
270,778
الربح لكل سهم
-3
العائد الربحي
-
P/E
-1
حجم السوق
158,492,350
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    B
    BEAM
    -2.705
    (-8.16%)
    30.445 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    R
    RGEN
    -3.710
    (-2.28%)
    158.950 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    TMO
    TMO
    -5.71
    (-1.06%)
    532.28 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Editas Medicine

القطاع: Healthcare
الصناعة: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.